ulobetasol propionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 1349 66852-54-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • halobetasol propionate
  • ulobetasol propionate
  • miracorten
used in ointment to treat psoriasis; Ulobetasol cream contains 0.05% 6-fluoroclobetasol 17-propionate
  • Molecular weight: 484.96
  • Formula: C25H31ClF2O5
  • CLOGP: 3.53
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 80.67
  • ALOGS: -4.81
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.468 Moderate 0.76
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.084 Moderate 0.76
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 72.611 10^-6 cm/s Moderate 0.76
dh-clint Dog hepatocyte intrinsic clearance 72.611 uL/min/10^6 cells Moderate 0.76
dppb Dog plasma protein binding (% unbound) 2.700 % Moderate 0.76
fcs-ppb Fetal calf serum protein binding (% unbound) 4.450 % Moderate 0.76
herg hERG pIC50 4.814 pIC50 Moderate 0.76
hh-clint Human hepatocyte intrinsic clearance 59.020 uL/min/10^6 cells Moderate 0.76
hlm-clint Human liver microsomal intrinsic clearance 216.770 uL/min/mg protein Moderate 0.76
hppb Human plasma protein binding (% unbound) 2.800 % Moderate 0.76
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK 19
kinase-selectivity-class GRK2,MAP2K6 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.051 Moderate 0.76
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.315 Moderate 0.76
mh-clint Mouse hepatocyte intrinsic clearance 133.968 Moderate 0.76
mppb Mouse plasma protein binding (% unbound) 2.360 Moderate 0.76
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 15.276 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 5.340 % Moderate 0.76
rat-kpuu-brain Rat brain Kpuu 0.354 % Moderate 0.76
rh-clint Rat hepatocyte intrinsic clearance 133.045 uL/min/10^6 cells Moderate 0.76
rh-fuinc Rat hepatocyte fraction unbound in incubation 18.260 % Moderate 0.76
rppb Rat plasma protein binding (% unbound) 1.900 % Moderate 0.76
solubility-dd Solubility at pH 7.4 in DMSO 12.218 uM Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
Dec. 17, 1990 FDA RANBAXY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 139.14 27.69 66 1861 147688 90478832
Dermatitis atopic 73.50 27.69 25 1902 23447 90603073
Drug ineffective 60.82 27.69 106 1821 1384192 89242328
Product use in unapproved indication 58.86 27.69 52 1875 336184 90290336
Noninfective encephalitis 51.15 27.69 9 1918 523 90625997
Product dose omission issue 37.35 27.69 38 1889 291649 90334871
Dry skin 36.68 27.69 23 1904 88050 90538470
Suspected COVID-19 36.62 27.69 9 1918 2677 90623843
Papule 30.93 27.69 10 1917 7992 90618528
Actinic keratosis 30.25 27.69 8 1919 3180 90623340
Skin exfoliation 28.93 27.69 18 1909 67895 90558625

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 136.41 40.37 49 975 48555 42571756
Drug ineffective 97.85 40.37 95 929 630102 41990209
Dermatitis atopic 64.62 40.37 20 1004 12384 42607927

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 163.90 24.75 71 2094 139922 110447212
Dermatitis atopic 85.38 24.75 28 2137 25513 110561621
Dry skin 54.64 24.75 31 2134 107622 110479512
Noninfective encephalitis 42.80 24.75 8 2157 708 110586426
Skin exfoliation 35.94 24.75 22 2143 87629 110499505
Product dose omission issue 33.25 24.75 36 2129 321746 110265388
Pruritus 31.32 24.75 47 2118 581513 110005621
Suspected COVID-19 30.18 24.75 8 2157 3485 110583649
Drug ineffective 28.45 24.75 79 2086 1520461 109066673
Eczema 26.73 24.75 17 2148 72276 110514858
Trichophytosis 26.36 24.75 5 2160 479 110586655
Injection site pain 25.90 24.75 24 2141 177898 110409236

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05AX55 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR TOPICAL USE
Other antipsoriatics for topical use
ATC D07AC21 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, potent (group III)
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014662 Vasoconstrictor Agents
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic

Related Drugs by ATC class:

D05AX Other antipsoriatics for topical use 7 drugs
calcipotrienecalcitriolfumaric acidroflumilasttacalcitoltapinaroftazarotene
D07AC Corticosteroids, potent (group III) 20 drugs
amcinonidebeclometasone dipropionatebetamethasonebudesonidedesoximetasonediflorasone diacetatediflucortolonedifluprednatefluclorolonefludroxycortidefluocinolone acetonidefluocinonide show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Skin ulcer contraindication 46742003
Hypopituitarism contraindication 74728003 DOID:9406
Fissure in skin contraindication 95321009
Skin irritation contraindication 367466007
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
Denuded skin contraindication 418242004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.48 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.01%;0.045% DUOBRII BAUSCH N209354 April 25, 2019 RX LOTION TOPICAL 10478502 Nov. 2, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01%;0.045% DUOBRII BAUSCH N209354 April 25, 2019 RX LOTION TOPICAL 11839656 Nov. 2, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01%;0.045% DUOBRII BAUSCH N209354 April 25, 2019 RX LOTION TOPICAL 11986527 Nov. 2, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01% BRYHALI BAUSCH N209355 Nov. 6, 2018 RX LOTION TOPICAL 10478502 Nov. 2, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01% BRYHALI BAUSCH N209355 Nov. 6, 2018 RX LOTION TOPICAL 11839656 Nov. 2, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01% BRYHALI BAUSCH N209355 Nov. 6, 2018 RX LOTION TOPICAL 11986527 Nov. 2, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.05% ULTRAVATE LACER PHARMA N208183 Nov. 6, 2015 RX LOTION TOPICAL 8962028 June 19, 2033 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
0.01%;0.045% DUOBRII BAUSCH N209354 April 25, 2019 RX LOTION TOPICAL 10426787 June 6, 2036 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01%;0.045% DUOBRII BAUSCH N209354 April 25, 2019 RX LOTION TOPICAL 11648256 June 6, 2036 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.01%;0.045% DUOBRII BAUSCH N209354 April 25, 2019 RX LOTION TOPICAL 11679115 June 6, 2036 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
0.05% LEXETTE MAYNE PHARMA N210566 May 24, 2018 DISCN AEROSOL, FOAM TOPICAL 11020407 Nov. 30, 2036 FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4019575 VUID
N0000147674 NUI
D04409 KEGG_DRUG
4019575 VANDF
4019773 VANDF
CHEBI:135782 CHEBI
CHEMBL1200908 ChEMBL_ID
C064466 MESH_SUPPLEMENTAL_RECORD_UI
6918178 PUBCHEM_CID
DB00596 DRUGBANK_ID
41208 RXNORM
4815 MMSL
63970 MMSL
003564 NDDF
003565 NDDF
126085005 SNOMEDCT_US
764616008 SNOMEDCT_US
764617004 SNOMEDCT_US
C0098735 UMLSCUI
C0082787 UMLSCUI
5311167 PUBCHEM_CID
91A0K1TY3Z UNII
91A0K1TY3Z INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bryhali HUMAN PRESCRIPTION DRUG LABEL 1 0187-0002 LOTION 0.10 mg TOPICAL NDA 24 sections
Duobrii HUMAN PRESCRIPTION DRUG LABEL 2 0187-0653 LOTION 0.10 mg TOPICAL NDA 25 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0339 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0640 CREAM 0.50 mg TOPICAL ANDA 21 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 21922-108 OINTMENT 0.50 mg TOPICAL ANDA 18 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 42254-250 CREAM 0.50 mg TOPICAL ANDA 22 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 45802-129 CREAM 0.50 mg TOPICAL ANDA 21 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 45802-131 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
LEXETTE HUMAN PRESCRIPTION DRUG LABEL 1 51862-618 AEROSOL, FOAM 0.50 mg TOPICAL ANDA 26 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 52565-073 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 52959-961 OINTMENT 0.50 mg TOPICAL ANDA 22 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 54868-4907 CREAM 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5482 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 63629-8664 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 63629-8665 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
Halobetasol propionate HUMAN PRESCRIPTION DRUG LABEL 1 68308-769 AEROSOL, FOAM 0.50 mg TOPICAL ANDA 28 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 70752-119 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 72162-1396 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2067 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2258 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2331 CREAM 0.50 mg TOPICAL ANDA 20 sections
ULTRAVATE HUMAN PRESCRIPTION DRUG LABEL 1 73159-008 LOTION 0.50 mg TOPICAL NDA 26 sections
Halobetasol Propionate HUMAN PRESCRIPTION DRUG LABEL 1 85437-008 LOTION 0.50 mg TOPICAL NDA authorized generic 26 sections